Companies › X4 Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 3; Hematology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Mavorixafor C-X-C chemokine receptor type 4 antagonist | CXCR4 | Phase 3 | Neutropenia | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06056297 | Mavorixafor | Phase 3 | Neutropenia | Hematology | Sep 2027 |
Cash and short-term investments of $188m on 2026-09-30; operating cash outflow about $81m a year; runway about 28 months at that burn, to Jan 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical Gritgen Therapeutics Forma Therapeutics Wuhan Createrna Science and Technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.